MedTrace Logo

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

NCT03346538 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-05-22

Study results available
· View outcomes & findings →

Summary

To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Continuous infusion high-dose MCI-186

intravenous injection

DRUG

Continuous infusion low-dose MCI-186

intravenous injection

DRUG

Continuous infusion placebo

intravenous injection

DRUG

Approved dosing regimen MCI-186

intravenous injection

DRUG

Approved dosing regimen placebo

intravenous injection

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Tanabe Pharma Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-17
Primary Completion
2018-05-14
Completion
2018-05-14

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03346538 on ClinicalTrials.gov